Inebilizumab
UPLIZNA (inebilizumab) is a prescription monoclonal antibody that targets CD19 on immune cells. It's administered intravenously for certain autoimmune conditions. Manufactured by Viela Bio and Horizon Therapeutics, it's available as a 10 mg/mL solution in single-dose vials. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | UPLIZNA (inebilizumab) is a prescription monoclonal antibody that targets CD19 on immune cells. It's administered intravenously for certain autoimmune conditions. Manufactured by Viela Bio and Horizon Therapeutics, it's available as a 10 mg/mL solution in single-dose vials. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Inebilizumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Inebilizumab — ANDA 761142 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761142"
}
]
|
| identifier | ANDA761142 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"fda",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Inebilizumab |
